All In Biotech

Drug Trial Radar · NCT07397338

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

370

Planned (sponsor's estimate)

Start

Jan 30, 2026

Primary completion

May 2029

Study completion May 2029

Sponsor

Lead sponsor
Revolution Medicines, Inc.Industry
Sponsor type
Industry
Collaborators
Summit Therapeutics
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

Conditions

  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Non-small Cell Lung Cancer (NSCLC)
  • NSCLC
  • Colorectal Cancer (CRC)
  • CRC

Interventions

  • DaraxonrasibDrug

    oral tablets

  • ElironrasibDrug

    oral tablets

  • ZoldonrasibDrug

    oral tablets

  • IvonescimabDrug

    IV infusion

  • Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)Drug

    IV infusion

  • cetuximab (Cohort C2 Only)Drug

    IV infusion

  • Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)Drug

    IV infusion

  • Daraxonrasib (Cohort B1 only)Drug

    oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with adverse events (AEs)Time frame: Up to approximately 4 years
  2. Changes in vital signsTime frame: Up to approximately 4 years
  3. Changes in clinical laboratory test valuesTime frame: Up to approximately 4 years
  4. Dose Limiting ToxicitiesTime frame: 28 days

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut · Recruiting

  • University of Kentucky HealthCare (UK HealthCare)

    Lexington, Kentucky · Recruiting

  • Health Partners Cancer Center at Regions Hospital

    Saint Paul, Minnesota · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - NYU POC

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • The Jame Outpatient Care West Campus

    Columbus, Ohio · Recruiting

  • OHSU Knight Cancer Institute

    Portland, Oregon · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.